A Hidden Tradeoff in Trump’s MFN Drug Deals

It’s not a straight line from manufacturer discounts to patient savings. The American healthcare system is a complex tangle of pre-existing agreements between manufacturers, insurers, pharmacy benefit managers and pharmacies that dictate drug prices, according to Paul Pruitt, Chief Growth Officer of SHARx, a prescription advocacy and procurement program. Simply lowering a manufacturer’s price doesn’t necessarily mean patients will pay less.